[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 45, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.02, "open": 4.94, "dayLow": 4.91, "dayHigh": 5.08, "regularMarketPreviousClose": 5.02, "regularMarketOpen": 4.94, "regularMarketDayLow": 4.91, "regularMarketDayHigh": 5.08, "beta": 1.516, "forwardPE": -3.0670733, "volume": 138572, "regularMarketVolume": 138572, "averageVolume": 261692, "averageVolume10days": 191350, "averageDailyVolume10Day": 191350, "bid": 5.02, "ask": 5.06, "bidSize": 100, "askSize": 100, "marketCap": 337506976, "fiftyTwoWeekLow": 2.689, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 5.2316, "twoHundredDayAverage": 5.12415, "currency": "USD", "enterpriseValue": 217741008, "floatShares": 35019594, "sharesOutstanding": 67098800, "sharesShort": 3928898, "sharesShortPriorMonth": 3955289, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0586, "heldPercentInsiders": 0.0051200003, "heldPercentInstitutions": 0.97743, "shortRatio": 13.25, "shortPercentOfFloat": 0.0631, "impliedSharesOutstanding": 67098800, "bookValue": 1.521, "priceToBook": 3.307035, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -88562000, "trailingEps": -1.44, "forwardEps": -1.64, "pegRatio": -0.23, "enterpriseToEbitda": -2.364, "52WeekChange": 0.3449198, "SandP52WeekChange": 0.34083736, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.03, "targetHighPrice": 40.0, "targetLowPrice": 13.0, "targetMeanPrice": 19.0, "targetMedianPrice": 15.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 144523008, "totalCashPerShare": 2.304, "ebitda": -92104000, "totalDebt": 46710000, "quickRatio": 9.299, "currentRatio": 9.842, "debtToEquity": 49.47, "returnOnAssets": -0.37866002, "returnOnEquity": -0.88556, "freeCashflow": -55052124, "operatingCashflow": -85546000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]